IntrepidX hires Hatch-Waxman eDiscovery veteran Taylor Judd

IntrepidX named Taylor Judd director of business development as the legal services firm pushes deeper into pharmaceutical litigation and other complex eDiscovery work. The hire adds more than 15 years of experience in Hatch-Waxman matters, corporate legal workflows and data-heavy reviews.

Why it matters: - IntrepidX is trying to grow in pharmaceutical litigation, a niche where speed, confidentiality and defensible workflows can decide outcomes. - The hire also supports broader demand for eDiscovery help in banking, finance, e-commerce and corporate legal operations. - IntrepidX is pairing business development with technology investments designed to reduce friction across the review process.

What happened: - IntrepidX said Taylor Judd joined as director of business development on July 23, 2026. - Judd will support strategic growth across pharmaceutical litigation, corporate legal work and other complex eDiscovery matters. - IntrepidX said the expansion also covers banking and finance and e-commerce clients. - Judd previously worked with Parkash Khatri and other IntrepidX leaders earlier in his career.

The details: - Judd brings more than 15 years of experience helping law firms and corporate legal teams manage discovery, review and data workflows. - His background includes Hatch-Waxman and pharmaceutical IP litigation, including ANDA-related disputes, joint defense coordination and review strategy for major pharmaceutical companies and their law firms. - Judd has also worked across banking and finance, e-commerce and other corporate environments. - His work has included internal investigations, employee departure workflows, contract and policy review, HR document updates and other data-intensive initiatives. - Those matters required legal-grade processes, strict confidentiality and protection of intellectual property, customer data and personally identifiable information. - IntrepidX has gained industry recognition for innovation in Relativity workflows. - IntrepidX said XSuite is its lineup of applications that work in or alongside Relativity to reduce friction across the eDiscovery lifecycle. - XSuite includes near-instant document viewing with page-load times as fast as 4 milliseconds. - XSuite also includes integrated coding and review workflows, built-in translation, advanced text search, image highlighting and AI-powered OCR. - IntrepidX said the OCR can extract text from handwritten notes, degraded scans and complex legacy documents that traditional OCR often misses. - Parkash Khatri said Judd brings market knowledge, client relationships and specialized experience that align with IntrepidX’s direction. - Judd said the company’s specialization is real and its technology helps solve problems faster than larger providers can. - Judd also said that combination matters in markets with sensitive intellectual property, personal information, complex data and tight timelines. - Judd said IntrepidX is well positioned for corporate legal teams that need defensible process, strong technology and disciplined handling of sensitive information. - Judd said Khatri’s technical fluency and speed are a major advantage for the company.

Between the lines: - IntrepidX is signaling that its growth strategy is not just about adding sales capacity. - The company is trying to sell specialized legal expertise plus workflow software to clients facing high-stakes, regulated matters. - Judd’s prior relationship with the leadership team suggests IntrepidX is leaning on familiar industry ties as it expands.

What's next: - IntrepidX said it will continue building a team focused on high-touch client service, specialized legal workflows and practical innovation. - The company is targeting complex matters across highly regulated and data-sensitive industries. - More information is available on IntrepidX's website. - The company also posted an update on LinkedIn.

The bottom line: - IntrepidX is betting that niche litigation expertise and faster eDiscovery tools will help it win more work in pharmaceutical and corporate legal markets.